Navigation Links
ProMetic to present at Merriman Curhan Ford's Investor Summit 2008 on September 16th
Date:9/12/2008

Hundreds of Institutional Investors to Attend Conference

MONTREAL, Sept. 12 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic"), today announced that Mr. Pierre Laurin, President and Chief Executive Officer, will present at Merriman Curhan Ford's 5th annual Investor Summit on September 16, 2008 at 16:00 (PDT). This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

More information about the conference can be found at: http://www.mcfco.com.

About Merriman Curhan Ford

Merriman Curhan Ford (NASDAQ:MERR) is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to http://www.mcfco.com.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.


'/>"/>
SOURCE Prometic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
2. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
3. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
4. Prometic provides information for its Annual and Special Meeting of Shareholders
5. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
6. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
7. Prometic to present at the American Chemical Society
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
10. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
11. ProMetic provides business update - Over $35 million worth of business secured in January
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... of their $7M Series B financing, adding an additional ... $3.5M led by Mesa Verde Venture Partners and other ... will be directed towards further accelerating commercial adoption of ... genomic profiling test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
Breaking Biology Technology:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):